In addition, numerous investigations have shown that SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, luseogliflozin, and ipragliflozin) help protect against atherosclerosis by improving metabolic parameters. This evidence concerns the gene SLC5A2 and atherosclerosis.